Neuraxpharm launches Tapimio® (tapentadol) prolonged release capsules in the UK Neuraxpharm announced on June 30th 2022 the launch of Tapimio® (tapentadol) for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics. Tapimio® is the first and only prolonged release capsule formulation of tapentadol to be made available…
Category: Pain
Promising interim results for Ajovy
PEARL STUDY Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment. 25th June 2022: Teva Pharmaceuticals Europe B.V. announced promising interim results from its Pan-European Real World study (PEARL),…
